- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05457114
Sammenheng mellom bruk av lungearteriekateter og kliniske resultater etter levertransplantasjon
The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.
Studieoversikt
Status
Detaljert beskrivelse
Pulmonary artery catheter (PAC) has been used for advanced hemodynamic monitoring during liver transplantation. However, recent advances in less invasive monitoring could provide continuous cardiac output monitoring by arterial waveform analysis. Using this technology, stroke volume variation (SVV) is monitored as a preload index. Calculated systemic vascular resistance (SVR) can be monitored if central venous pressure (CVP) is provided. Therefore, this less invasive form of hemodynamic monitoring may replace the PAC. The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Seoul, Sør -Korea, 03080
- Seoul National University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients received liver transplantation surgery in a single tertiary care university hospital
Beskrivelse
Inclusion Criteria:
- Adult patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2006 and 2022
Exclusion Criteria:
- Patients with baseline renal dysfunction
- Missing baseline or outcome variables
- Retransplantation
- Patients who received intraoperative transesophageal echocardiography (TEE) monitoring
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Pulmonary artery catheter group
Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters |
PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA) |
|
Non-pulmonary artery catheter group
Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo |
Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with acute kidney injury
Tidsramme: the first 7 postoperative days
|
Acute kidney injury (AKI) was defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria, which was defined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase from baseline level or increase in serum creatinine to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent serum creatinine level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
|
Number of Participants with early allograft dysfunction
Tidsramme: the first 7 postoperative days
|
Early allograft dysfunction (EAD) was defined when one or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, prothrombin time: international normalized ratio ≥ 1.6, or aspartate or alanine transaminase > 2000 IU/L |
the first 7 postoperative days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
In-hospital mortality
Tidsramme: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Tidsramme: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of hospital stay
Tidsramme: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
|
Length of intensive care unit (ICU) stay
Tidsramme: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- H-2205-117-1327
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .